【摘要】 轻度认知障碍的实际发病率较高，对人们的日常生活影响较大，但是其发现较为困难，这对该疾病的早期诊断与治疗以及病程监测等方面提出了全新的挑战。轻度认知障碍生物标志物的发现将为该疾病的诊疗提供适时的帮助，最近，代谢组学技术在轻度认知障碍的生物标志物发现方面展示了许多新的研究结果。综述了近期代谢组学技术在轻度认知障碍研究中的重要发现，包括关键代谢物的鉴定、代谢途径的异常及其与轻度认知障碍病理生理过程的联系等。代谢组学技术的应用将为轻度认知障碍的早期诊断及个性化治疗等领域的发展提供新的思路和重要理论基础。更多还原

【Abstract】 The actual incidence rate of mild cognitive impairment(MCI) is relatively high, and it has a significant impact on people’s well-being, but its discovery is relatively difficult, which poses a new challenge for early diagnosis treatment and the monitoring of the course of the disease. Biomarkers for MCI could provide timely assistance in its diagnosis and treatment. Recently, metabolomics technology has demonstrated promising results in identifying biomarkers for MCI. Therefore we review the key findings of metabolomics in MCI research, including the identification of crucial metabolites, abnormalities in metabolic pathways and their association with the pathophysiological processes of MCI. The application of metabolomics technology could provide new insights and important theoretical foundations for the development of the early diagnosis, precision medicine, and personalized treatment strategies of MCI.更多还原